Sunday, 22 April 2018

Lupin, Cadila start drug recalling from US market

08 December 2017 | News

The ongoing voluntary nationwide recall is a class III recall.

Image credit- dogingpost.com

Image credit- dogingpost.com

Drug firms Cadila Healthcare and Lupin have started recalling nearly 1.11 lakh units of Duloxetine delayedrelease capsules and 19,812 bottles of Paroxetine tablets, respectively, from the US market.

According to the USFDA, 1,11,648 units of Duloxetine delayed-release capsules USP, in the strength of 30 mg, is being recalled by Lupin on account of failed dissolution specification. The drug was manufactured by Lupin Goa. The ongoing voluntary nationwide recall is a class III recall.

Zydus Pharmaceuticals USA Inc, arm of Cadila Healthcare, is also recalling 19,812 bottles of Paroxetine tablets in the strength of 30 mg from the US market.

The reason for the voluntary nationwide recall is the presence of foreign tablets or capsules, as Risperidone tablets were found in bottle of Paroxetine tablets. The product was manufactured by Cadila Healthcare.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account





Survey Box

Can access to vaccines reduce the threat of antibiotic resistance?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls